Twist Bioscience Corp: directors' dealings · United States · SEC (Form 4)

About Twist Bioscience Corp

Twist Bioscience Corp. (NASDAQ: TWST) is a United States-based life sciences company listed on the NASDAQ market in the United States. Founded in 2013 and headquartered in South San Francisco, California, Twist has built its business around a proprietary silicon-based DNA synthesis platform. That platform is designed to manufacture synthetic DNA at scale with speed, precision, and potentially lower unit economics than many legacy approaches. The company serves customers across research life sciences, biopharma, diagnostics, agriculture, and broader synthetic biology applications. Twist’s core business is centered on nucleic acid synthesis and genomics-enabled tools. Its product portfolio includes synthetic genes, gene fragments, library preparation kits for sequencing workflows, target enrichment products, oncology-focused next-generation sequencing panels, and other consumables used in molecular biology and genomic research. In practical terms, Twist is not just a reagent supplier; it is a platform company that supports the upstream workflows used by academic labs, biotech firms, pharmaceutical companies, and translational research centers. This makes the business strategically important in workflows where sequence accuracy, turnaround time, and scalability matter. From a competitive standpoint, Twist operates in a highly specialized and innovation-driven market. Its differentiation comes from its silicon-based synthesis technology, which is a meaningful industrial advantage in a sector where customers increasingly demand higher throughput, more complex designs, and reliable supply. The company competes on product performance, workflow integration, and breadth of applications, especially in next-generation sequencing, oncology research, and nucleic-acid therapeutics research. Its growing portfolio suggests a deliberate move toward more integrated, higher-value solutions rather than standalone DNA orders. Recent company developments have reinforced that strategy. In 2025 and early 2026, Twist announced multiple product launches, including new plasmid preparation offerings, next-generation library preparation kits, expanded complex gene capabilities, and broader oncology genomic profiling solutions. Twist also expanded and advanced its collaboration with Element Biosciences to develop integrated sequencing workflows, underscoring its ambition to become more deeply embedded in the NGS ecosystem. These actions indicate a continued focus on product innovation, broader addressable markets, and deeper penetration into applied genomics workflows. For investors, Twist remains a growth-oriented biotechnology tools company with exposure to research spending cycles and biotech funding conditions. At the same time, its differentiated platform, recurring consumables model, and expanding product suite position it as a notable specialist in synthetic biology and genomics tools within the United States market.